Physician profile
John M Byrnes
NPI 1700846334
$2,779.75
in general payments reported to CMS, 2019-2025
35 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $315 · 2021: $212 · 2022: $570 · 2023: $488 · 2024: $386 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.20 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $339.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Ucb, INC. | $335.30 | 2019-2024 | Fintepla |
| Indivior INC. | $214.81 | 2019-2025 | Sublocade |
| Novo Nordisk INC | $187.84 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Orexo US, INC. | $184.49 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $166.90 | 2019-2023 | Breztri, Farxiga |
| Jazz Pharmaceuticals INC. | $135.14 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $109.22 | 2022 | |
| Pfizer INC. | $86.69 | 2019-2023 | |
| Astellas Pharma US INC | $73.00 | 2023-2025 | Veozah |
| Nevro Corp. | $65.24 | 2022 | |
| Xeris Pharmaceuticals, INC. | $64.17 | 2023 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $63.17 | 2024-2025 | Inspire |
| Sunovion Pharmaceuticals INC. | $60.17 | 2019-2022 | |
| Eisai INC. | $57.81 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $55.74 | 2023-2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $52.17 | 2019-2025 | Xyosted |
| Vanda Pharmaceuticals INC. | $46.06 | 2022-2023 | Hetlioz |
| Conmed Corporation | $40.00 | 2019 | |
| Gilead Sciences, INC. | $38.43 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.42 | 2024-2025 | Caplyta |
| Vistapharm, INC. | $37.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $36.94 | 2019 | |
| Abbvie INC. | $36.36 | 2022-2024 | |
| Glaxosmithkline, LLC. | $34.83 | 2020-2023 | Shingrix |
| Alkermes, INC. | $32.95 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $29.84 | 2020-2022 | |
| Axsome Therapeutics, INC. | $27.89 | 2024 | Sunosi |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
| Azurity Pharmaceuticals, INC. | $19.28 | 2025 | Azmiro |
| Dexcom, INC. | $19.01 | 2024 | Dexcom G6 Transmitter |
| Rhodes Pharmaceuticals L.P. | $16.44 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.13 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.88 | 2022 | |
| Merck Sharp & Dohme LLC | $15.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Byrnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.